Beximco Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
Beximco Pharmaceuticals has been growing earnings at an average annual rate of 10.3%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 13.7% per year. Beximco Pharmaceuticals's return on equity is 10.6%, and it has net margins of 12.4%.
Anahtar bilgiler
10.3%
Kazanç büyüme oranı
10.3%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 11.0% |
| Gelir büyüme oranı | 13.7% |
| Özkaynak getirisi | 10.6% |
| Net Marj | 12.4% |
| Son Kazanç Güncellemesi | 31 Mar 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Beximco Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 24 | 43,085 | 5,330 | 10,873 | 0 |
| 31 Dec 23 | 41,652 | 4,916 | 10,706 | 0 |
| 30 Sep 23 | 40,639 | 4,720 | 10,691 | 0 |
| 30 Jun 23 | 39,267 | 4,614 | 10,214 | 0 |
| 31 Mar 23 | 37,974 | 4,477 | 10,033 | 0 |
| 31 Dec 22 | 37,379 | 4,629 | 9,592 | 0 |
| 30 Sep 22 | 35,987 | 5,105 | 9,463 | 0 |
| 30 Jun 22 | 34,669 | 5,123 | 9,101 | 0 |
| 31 Mar 22 | 33,660 | 5,738 | 8,887 | 0 |
| 31 Dec 21 | 32,062 | 6,097 | 8,393 | 0 |
| 30 Sep 21 | 31,037 | 5,519 | 7,837 | 0 |
| 30 Jun 21 | 29,494 | 5,128 | 7,470 | 0 |
| 31 Mar 21 | 28,269 | 4,578 | 6,918 | 0 |
| 31 Dec 20 | 27,517 | 4,017 | 6,802 | 0 |
| 30 Sep 20 | 26,235 | 3,724 | 6,581 | 0 |
| 30 Jun 20 | 25,612 | 3,515 | 6,451 | 0 |
| 31 Mar 20 | 25,056 | 3,405 | 6,221 | 0 |
| 31 Dec 19 | 24,202 | 3,251 | 6,068 | 0 |
| 30 Sep 19 | 23,735 | 3,143 | 5,900 | 0 |
| 30 Jun 19 | 22,817 | 3,033 | 5,689 | 0 |
| 31 Mar 19 | 21,724 | 2,852 | 5,470 | 0 |
| 31 Dec 18 | 20,188 | 2,708 | 5,053 | 0 |
| 30 Sep 18 | 18,823 | 2,647 | 4,661 | 0 |
| 30 Jun 18 | 17,717 | 2,537 | 4,356 | 0 |
| 31 Mar 18 | 16,924 | 2,513 | 4,159 | 0 |
| 31 Dec 17 | 16,517 | 2,431 | 4,054 | 0 |
| 30 Sep 17 | 16,022 | 2,356 | 3,983 | 0 |
| 30 Jun 17 | 15,509 | 2,227 | 3,829 | 0 |
| 31 Mar 17 | 14,687 | 2,224 | 3,480 | 0 |
| 31 Dec 16 | 14,271 | 2,133 | 3,390 | 0 |
| 30 Sep 16 | 13,736 | 2,060 | 3,342 | 0 |
| 30 Jun 16 | 13,356 | 1,965 | 3,263 | 0 |
| 31 Dec 15 | 12,966 | 1,954 | 3,266 | 0 |
| 30 Sep 15 | 12,573 | 1,804 | 3,082 | 0 |
| 30 Jun 15 | 12,134 | 1,813 | 2,992 | 0 |
| 31 Mar 15 | 11,628 | 1,605 | 2,867 | 0 |
| 31 Dec 14 | 11,207 | 1,528 | 2,755 | 0 |
| 30 Sep 14 | 11,139 | 1,476 | 2,806 | 0 |
| 30 Jun 14 | 10,847 | 1,471 | 2,732 | 0 |
| 31 Mar 14 | 10,804 | 1,452 | 2,686 | 0 |
| 31 Dec 13 | 10,491 | 1,405 | 2,619 | 0 |
Kaliteli Kazançlar: BXPHARMA has high quality earnings.
Büyüyen Kar Marjı: BXPHARMA's current net profit margins (12.4%) are higher than last year (11.8%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: BXPHARMA's earnings have grown by 10.3% per year over the past 5 years.
Büyüme Hızlandırma: BXPHARMA's earnings growth over the past year (19.1%) exceeds its 5-year average (10.3% per year).
Kazançlar vs. Sektör: BXPHARMA earnings growth over the past year (19.1%) exceeded the Pharmaceuticals industry -2.8%.
Özkaynak Getirisi
Yüksek ROE: BXPHARMA's Return on Equity (10.6%) is considered low.